Concurrent Chemoradiotherapy (CCRT) for Stage I-II Esophageal Cancer Patients
نویسندگان
چکیده
منابع مشابه
Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study
Nimotuzumab is a humanized anti-epidermal growth factor receptor IgG1 monoclonal antibody. This phase I study assessed the tolerability, safety, efficacy, and pharmacokinetics of nimotuzumab in combination with chemoradiotherapy in Japanese patients with esophageal cancer. Patients with stage II, III, and IV esophageal cancer were enrolled. Patients were planned to receive nimotuzumab (level 1:...
متن کاملA Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer
BACKGROUND Concurrent chemoradiotherapy is a standard treatment for local advanced esophageal cancer, but the outcomes are controversial. Our goals were to compare the therapeutic effects of concurrent chemoradiotherapy and radiotherapy alone in local advanced esophageal cancer using meta-analysis. METHODS MEDLINE, EMBASE and the Cochrane library were searched for studies comparing chemoradio...
متن کاملSurvival Outcomes and Toxicity of Concurrent Chemoradiotherapy for Esophageal Cancer
Aims: The aim of the study was to investigate the impact of chemoradiotherapy(CRT) on survival of patients with unresectable esophageal cancer treated with radiotherapy combined with either concurrent DCF [docetaxel, cisplatin +5-fluorouracil(5-FU)] or CF [cisplatin and 5-FU).Patients and methods:Data of patients who underwent CRT for esophageal cancer during 2010 and 2015 in the department of ...
متن کاملA phase I study of concurrent chemoradiotherapy and cetuximab for locally advanced esophageal cancer.
AIM To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of concurrent chemoradiotherapy and cetuximab in patients with non-resectable locally advanced esophageal cancer. PATIENTS AND METHODS Escalating doses of oxaliplatin every second week and daily tegafur/uracil were given concurrently with radiotherapy, 59.4 Gy in 33 fractions. Cetuximab was given on day 15 (...
متن کاملTreatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer
PURPOSE To evaluate treatment outcomes and determine prognostic factors in patients with esophageal cancer treated with esophagectomy after neoadjuvant chemoradiotherapy (NCRT). MATERIALS AND METHODS We retrospectively evaluated 39 patients with esophageal cancer who underwent concurrent chemoradiotherapy followed by esophagectomy between 2002 and 2012. Initial clinical stages of patients wer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Radiation Oncology*Biology*Physics
سال: 2018
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2018.07.511